Product Description

Overall, the U.S. diabetes monitoring, treatment and drug delivery market was valued at nearly $48 billion in 2024. This is expected to increase over the forecast period at a CAGR of 7.3% to reach $79 billion in 2031.

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin and GLP-1 receptor agonists such as Ozempic®, insulin pens, insulin syringes and insulin pumps.

The largest and fastest-growing segment of the diabetes care market in 2024 was the insulin and GLP-1 market, which accounted for the majority of the total market value. The growth of the GLP-1 market in recent years has been driven by a confluence of various dynamic factors. The rapid growth of this segment is largely attributed to the increasing demand for more effective and innovative treatment options for both type 2 diabetes and obesity, two chronic conditions that are becoming more prevalent on a global scale. The rising global burden of these diseases, along with the growing awareness of the need for improved management strategies, has created a heightened demand for advanced therapies that address both of these interconnected health concerns.

MARKET REPORT DATA TYPES INCLUDED

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Market Drivers & Limiters
• Market Forecasts Until 2031, and Historical Data to 2021
• Recent Mergers & Acquisitions
• Company Profiles and Product Portfolios
• Leading Competitors

U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET TRENDS

The market for smart reusable insulin pens is expected to grow steadily over time, as these devices offer advanced digital features that help individuals with diabetes manage their insulin doses more efficiently. Unlike traditional reusable insulin pens, smart insulin pens track insulin usage, calculate doses based on factors like carbohydrate intake or blood sugar levels, and provide reminders for injections. Although they tend to be priced higher than traditional models, the advanced technology is expected to lead to more consistent and improved diabetes management. As technology continues to progress, the demand for smart insulin pens is predicted to increase, offering enhanced convenience and better control for users.

U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET SHARE INSIGHTS

• Novo Nordisk was the leading competitor in the diabetes care market in 2024, which was attributed to its leading position in the insulin market and the second-leading position in the insulin pen market. Novo Nordisk held the leading position in the ultra-long-acting insulin and ultra-rapid acting insulin markets and the second-leading position in the long-acting insulin, premixed insulin and human insulin markets. Also, Novo Nordisk is the only player in the rapid acting insulin market. The company’s insulin product portfolio includes long-acting insulin analog, Levemir®; ultra-long-acting insulin analog, Tresiba®; ultra-long-acting insulin analog, Xultophy®; rapid-acting insulin analog, NovoRapid®; ultra-rapid-acting insulin, Fiasp®; insulin premixed insulin analog, NovoMix®; and human insulin, Novolin®. The company’s GLP-1 receptor agonists portfolio includes Ozempic® (semaglutide) and Rybelsus® (semaglutide, oral form).
• Eli Lilly was the second-leading competitor in 2024, which was primarily attributed to its second-leading position in the insulin market. Eli Lilly held the leading position in the premixed insulin, ultra-rapid-acting insulin and human insulin markets and the third leading position in the long-acting insulin market. The company’s product portfolio includes long-acting insulin analog biosimilar, Basaglar®; rapid-acting insulin analog, Humalog®; premixed insulin analog, Humalog® Mix; and human insulin, Humulin®. The company’s GLP-1 receptor agonists portfolio includes Trulicity (dulaglutide), Mounjaro (tirzepatide) and Zepbound.
• Dexcom was the third-leading competitor in 2024. The company held the dominant leading position in the continuous glucose monitoring (CGM) market, primarily attributed to the strong performance of G6®, which received approval in March 2018, and G7, which is the latest iteration of Dexcom’s CGM technology and received FDA approval in April 2023.

U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET SEGMENTATION SUMMARY

While this report suite contains all applicable market data, each of the markets are also available as stand alone MedCore reports. This allows you to get access to only the specific market segment research that you need. You can view all these included reports and segmentation here:

• Blood Glucose Meter Market – Further Segmented Into:
  • Device Type: Personal and Professional.
• Blood Glucose Test Strip Market – Further Segmented Into:
  • Device Type: Personal and Professional.
• Lancet Market – Further Segmented Into:
  • Device Type: Personal and Professional.
• Continuous Glucose Monitoring Market – Further Segmented Into:
  • Device Type: Personal and Professional.
• Flash Glucose Monitoring Market – Further Segmented Into:
  • Device Type: Reader and Sensors.
• Insulin and GLP-1 Market – Further Segmented Into:
  • Insulin Type: Long-Acting, Ultra-Long-Acting, Rapid-Acting, Ultra-Rapid-Acting, Premixed, and Human.
  • Diabetes Care: GLP-1 Injection and GLP-1 Oral.
  • Obesity Care: GLP-1 Injection.
• Insulin Pen Market – Further Segmented Into:
  • Device Type: Reusable Pen and Pen Needles.
• Insulin Syringe Market – Further Segmented Into:
  • Device Type: Conventional and Safety Syringes.
• Insulin Pump Market – Further Segmented Into:
  • Device Type: Durable, Patch, and Simple Pumps.

GLOBAL RESEARCH SCOPE

FREE Sample Report